Status:
COMPLETED
A Survey on Quetiapine Extended-release Tablets in Patients With Depression in Bipolar Disorder
Lead Sponsor:
Astellas Pharma Inc
Conditions:
Depression
Bipolar Disorder
Eligibility:
All Genders
Brief Summary
The purpose of this study is to evaluate the safety and effectiveness of quetiapine in actual clinical settings.
Detailed Description
This is a post-marketing use-result survey study required for products in Japan. The investigator will register the patient who have been taking this product for the first time within 14 days after th...
Eligibility Criteria
Inclusion
- Patients with depressive symptoms of bipolar disorder
- Patients who have previously not been treated with quetiapine fumarate (immediate-release formulations of quetiapine fumarate and Bipresso Extended-Release Tablets)
Exclusion
- None
Key Trial Info
Start Date :
January 15 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 19 2020
Estimated Enrollment :
369 Patients enrolled
Trial Details
Trial ID
NCT03403790
Start Date
January 15 2018
End Date
March 19 2020
Last Update
October 16 2024
Active Locations (47)
Enter a location and click search to find clinical trials sorted by distance.
1
Site JP00023
Aichi, Japan
2
Site JP00005
Akita, Japan
3
Site JP00002
Aomori, Japan
4
Site JP00012
Chiba, Japan